Stay updated with breaking news from Evogene Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
REHOVOT, Israel, Jan. 23, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. ,...
The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica's microbiome-based immuno-oncology drug, BMC128 REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ --...
Rapid advancements in biotechnology is a key factor expected to drive global market growth during the forecast period...
/PRNewswire/ -- The human microbiome therapeutics market is expected to grow by USD 732.95 million from 2022 to 2027. In addition, the momentum of the market...
Evogene Ltd. (NASDAQ:EVGN – Get Free Report) saw a significant decrease in short interest in December. As of December 15th, there was short interest totalling 187,200 shares, a decrease of 35.0% from the November 30th total of 287,800 shares. Based on an average daily volume of 144,100 shares, the days-to-cover ratio is presently 1.3 days. […]